Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Women who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be related to lasting blood vessel damage after the pregnancy but there are currently no specific treatment strategies to prevent this disease progression. This study addresses this public health issue by examining whether starting low dose aspirin therapy after pregnancy is an effective treatment for lasting blood vessel damage in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| placebo | Placebo Comparator | placebo pill taken once daily at bedtime for 12 weeks |
|
| aspirin | Experimental | 162mg aspirin taken once daily at bedtime for 12 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Aspirin | Drug | 162mg aspirin capsule |
| |
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| magnitude of microvascular endothelial function | skin blood flow response to acetylcholine delivered via intradermal microdialysis | baseline, 12 weeks |
| magnitude of brachial artery endothelial function | brachial artery flow mediated dilation | baseline, 12 weeks |
| magnitude of microvascular endothelin-1 mediated constriction | skin blood flow response to endothelin-1 delivered via intradermal microdialysis | baseline, 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| magnitude of microvascular nitric oxide-dependent dilation | skin blood flow response to acetylcholine + L-NAME delivered via intradermal microdialysis | baseline, 12 weeks |
Not provided
Inclusion Criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Anna Reid-Stanhewicz, PHD | Contact | 319-467-1732 | anna-stanhewicz@uiowa.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Iowa | Recruiting | Iowa City | Iowa | 52242 | United States |
Not provided
| ID | Term |
|---|---|
| D011225 | Pre-Eclampsia |
| ID | Term |
|---|---|
| D046110 | Hypertension, Pregnancy-Induced |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001241 | Aspirin |
| ID | Term |
|---|---|
| D012459 | Salicylates |
| D062385 | Hydroxybenzoates |
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
Not provided
Not provided
Not provided
Not provided
Not provided
double blind
| Drug |
placebo capsule |
|
| D006841 |
| Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |